Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

In patients who receive an organ transplant, their body considers this organ as foreign and attempts to destroy it. This is called rejection. All patients who receive an organ transplant, will take a combination of anti-rejection medications. These medications prevent the new organ from being rejected from the body. FTY720 is a new compound that helps prevent organ rejection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Fingolimod Hydrochloride

Criteria

Inclusion Criteria:

• First kidney transplantation

• Male and female patients

• Between 18 and 65 years old

Exclusion Criteria:

• Patient in need of multi-organ transplant

• Patients with history of cardiac arrest

• Patients with any past or present malignancy